

**Table 1. Baseline characteristics**

	Prasugrel group (n=250)	Clopidogrel group (n=250)	P value
Age: yrs	67.7±10.0	67.2±11.2	0.568
Male: n (%)	50 (20.4)	51 (20.4)	0.911
Hypertension: n (%)	186 (74.4)	186 (74.4)	1.000
Diabetes: n (%)	106 (42.4)	93 (37.2)	0.235
Dyslipidemia: n (%)	177 (70.8)	159 (63.6)	0.086
Smoking: n (%)	140 (56.0)	148 (59.2)	0.469
Body weight<50 kg: n (%)	25 (10.0)	22 (8.8)	0.646
eGFR: ml/min/1.73m <sup>2</sup>	73.5±23.1	73.5±23.1	0.428
Underlying disease: n (%)			0.207
Chronic CAD	134 (53.6)	148 (59.2)	
ACS	116 (46.4)	102 (40.8)	
Affected vessels: n (%)			0.230
Single vessel disease	175 (70.0)	187 (74.8)	
Multi-vessel disease	75 (30.0)	63 (25.2)	
Syntax score	14.0±9.3	12.1±8.0	0.013
Approach: n (%)			0.720
Radial	130 (52.0)	134 (53.6)	
Femoral	120 (48.0)	116 (46.4)	
PCI for LAD: n (%)	122 (48.8)	139 (55.6)	0.128
DES: n (%)	199 (79.6)	128 (51.2)	<0.0001
Anticoagulants: n (%)			
Warfarin	9 (3.6)	11 (4.4)	0.648
DOAC	9 (3.6)	13 (5.2)	0.383

eGFR, estimated glomerular filtration rate; CAD, coronary artery disease; ACS, acute coronary syndrome; PCI, percutaneous coronary intervention; LAD, left anterior descending artery; DES, drug-eluting stent; DOAC, direct oral anticoagulant.

\*Multi-vessel disease includes two-vessel, three-vessel and left main coronary artery diseases